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Background: The rapid and reliable detection of infectious agents is one of the most challenging tasks in scenarios
lacking well-equipped laboratory infrastructure, like diagnostics in rural areas of developing countries. Commercially
available point-of-care diagnostic tests for emerging and rare diseases are particularly scarce.
Results: In this work we present a point-of-care test for the detection of Orthopoxviruses (OPV). The OPV ABICAP
assay detects down to 1 × 104 plaque forming units/mL of OPV particles within 45 min. It can be applied to clinical
material like skin crusts and detects all zoonotic OPV infecting humans, including Vaccinia, Cowpox, Monkeypox, and
most importantly Variola virus.
Conclusions: Given the high sensitivity and the ease of handling, the novel assay could be highly useful for on-site
diagnostics of suspected Monkeypox virus infections in areas lacking proper laboratory infrastructure as well as rapid
on-site testing of suspected bioterrorism samples.
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OPV belong to the Poxviridae family and are large and
complex DNA viruses able to infect humans, causing se-
vere diseases [1]. Despite the successful eradication of
smallpox caused by Variola virus (VARV), zoonotic in-
fections with still circulating OPVs, namely Monkeypox
virus (MPXV), Cowpox virus (CPXV), and Vaccinia virus
(VACV) [2], remain a threat to an increasing number of
unvaccinated individuals [3]. Diagnostics and differenti-
ation of OPV from other rash-inducing agents [4] are
usually done by detection of either viral particles by
negative staining electron microscopy or viral DNA by
quantitative real-time PCR (qPCR), both requiring dedi-
cated laboratories. However, rapid and highly sensitive
point-of-care (POC) diagnostics are needed because of
the rising incidence of MPXV infections in rural Africa* Correspondence: SternD@rki.de
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(http://creativecommons.org/publicdomain/ze[5, 6] as well as the risk of a potential deliberate release
of Variola virus in the case of a bioterrorist attack [7, 8].
An ideal POC diagnostic system should be affordable,
sensitive, specific, simple enough to perform by untrained
persons, rapid and robust, free of sophisticated equipment,
and deliverable to those who need it [9]. The ABICAP
(Antibody Immuno Column for Analytical Processes)
immunofiltration system fulfills these criteria [10]. The
principle is based on a gravity-driven flow-through antigen
capture ELISA (Fig. 1). Compared to established lateral
flow assays or enzyme linked immunosorbent assays
(ELISAs), the ABICAP assay offers several advantages.
First, by immobilizing the capture antibody on a porous
frit, the active surface coated with antibody is much lar-
ger as compared to the surface of an ELISA well. Thus
the diffusion distance of the sample to the surface is greatly
reduced, enabling much shorter incubation times (minutes
instead of hours in the case of ELISA). Next, as the sample
passes through the filter, enrichment out of larger sample
volumes allows for a higher sensitivity of detection. Finally,le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 a ABICAP column with antibody-coated frit and handheld photometer device for readout at 525 nm (Senova, Weimar, Germany). b Schematic
representation of the ABICAP assay procedure. Plastic columns with capture antibody-coated frits are filled with sample to capture the viral particles
with the following steps: (1) Addition of pre-diluted sample material (sample dilution buffer), (2) washing with washing buffer, (3) addition of
biotinylated detection antibody, (4) washing with washing buffer, (5) addition of streptavidin-(SA) PolyHRP, (6) two successive washing steps
with washing and substrate buffer, (7) addition of precipitating TMB substrate, (8) final washing with substrate buffer, readout with a handheld
photometer device
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of ELISA-like enzymatic amplification steps enables much
higher sensitivity as compared to lateral flow assays. With
an assay time of 45 min it is fast, the columns can be
stored at ambient temperature, handling is simple, and the
results can be read out by eye or a handheld photometric
device.
In this work, we describe a rapid and sensitive detection
system based on the ABICAP technology that reliably de-
tects particles of different human-pathogenic OPV.
Methods
Antibodies and proteins
The diagnostic ABICAP is based on two monoclonal
antibodies (mAbs) targeting the OPV surface protein A27:
mAb A1/40 and mAb A3/710. Briefly, both antibodies
bind to A27 with high affinity (A1/40: 2.3 nM; A3/710:
4.3 nM) and recognize non-overlapping linear epitopeslocated in close proximity to the N-terminal heparin-
binding domain of A27 (A1/40: aa 24–38; A3/710: aa
13–27). Both antibodies have previously been selected
in an antigen capture ELISA, representing the best com-
bination to detect native VACV, CMLV, CPXV, ECTV, and
MPXV. Production, purification, storage, and biotinylation
of antibodies was performed as described previously [11].
The following reagent was obtained through the NIH
Biodefense and Emerging Infections Research Resources
Repository (BEI Resources), NIAID, NIH: Vaccinia virus
(WR) rA27 (NR-2622) with a C-terminal histidine tag,
recombinantly expressed from baculovirus.
Viruses
The virus panel used for development and validation
included VACV strain New York City Board of Health
(NYCBOH, VR-1536™, ATCC/LGC Standards GmbH,
Wesel, Germany) and CPXV strain GuWi [12]. Camelpox
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strain Nü-1, and MPXV strain MSF6 were kindly provided
by Prof. Dr. Hermann Meyer (Bundeswehr Institute of
Microbiology, Munich, Germany). The OPV ABICAP de-
tection system was additionally validated with two VARV
strains, VARV Solaiman 1974 and VARV Niger 1969.
Parapoxvirus (PPV) ORF D1701 was kindly provided by
Achim Rziha (Friedrich-Loeffler-Institute, Tübingen,
Germany) whereas herpes simplex virus 1 (HSV-1) was
isolated in our lab from a patient. Propagation and ti-
tration of viruses on cell culture was done according to
standard procedures [13]. Viruses were used as clarified
supernatant (HSV, PPV, MPXV, and VARV) or as semi-
purified viral particles by centrifugation through a 40%
sucrose cushion [13]. All viruses were used natively ex-
cept for MPXV which was heat-inactivated at 60 °C for
2 h. All work with live VARV was conducted within a
biosafety level 4 laboratory in accordance to guidelines
and approvals from the World Health Assembly Advis-
ory Committee on Variola Virus Research.
For final validation, a panel containing inactivated
(γ-irradiation) highly pathogenic viruses comprising
Yellow fever virus strain 17D, Ebola virus strain Zaire,
Marburg virus, VACV, and MPXV in Dulbecco’s Modi-
fied Eagle Medium was kindly provided by the P.R.O.B.E.
consortium. Viruses in this panel have been quantified by
quantitative real-time PCR using published assays [14, 15]
and were investigated in a blinded manner to test the suit-
ability of the ABICAP assay to discern highly pathogenic
viruses in a bioterrorist setting.
Clinical sample material
Clinical sample material tested in this work had been sent
to the Robert Koch Institute for poxvirus diagnostics.
Crust material and surface swabs were delivered dry and
suspended in 500 μL of phosphate buffered saline (PBS,
pH 7.4) without magnesium and calcium. Surface swabs
were thoroughly mixed on a vortexer while crusts were
homogenized in a Fastprep 24 homogenizer (MP Bio-
medicals, Eschwege, Germany) after addition of Precellys®
ceramic beads (1.4 mm; PEQLAB, Erlangen, Germany),
and DNA was prepared from 200 μL of sample using the
Qiagen Blood and Tissues Kit (Qiagen, Hilden, Germany)
according the manufacturer’s recommendations. Quanti-
tative real-time PCR for OPV diagnostics was performed
on 5 μL of isolated DNA, using rpo18 as target as pub-
lished previously [16]. The number of genome equivalents
(GE) contained in the samples was estimated based on the
published calibration curve of the rpo18 assay. To test the
specificity of the ABICAP assay, clinical samples negative
in the OPV PCR were also tested. For differential diagnos-
tics, different PCR assays targeting Molluscipox virus [17],
Parapox virus [18], Myxoma virus [19] were tested on
isolated DNA from homogenized crusts or swabs.Homogenized samples in PBS were tested in the
ABICAP assay after dilution in UCBS casein buffer
(SDT, Baesweiler, Germany).
OPV ABICAP assay
The preparation of ABICAP columns was done as de-
scribed before [10], using mAb A1/40 immobilized on
polyethylene filter frits contained inside the ABICAP
columns and biotinylated mAb A3/710 as the detection
antibody.
To this aim, polyethylene filter frits (Type 180; Porex,
Aachen, Germany) used for the coating of the capture
antibodies were activated by successive 10-min washes
with 96% ethanol, 50% ethanol, and 3 × coating buffer
(0.1 M NaHCO3/ Na2CO3, pH 9.5). All activating and
coating steps were done at room temperature under con-
stant stirring and vacuum. The frits were then coated with
7.5 μg/frit of mAb A1/40 in coating buffer (75 μg/mL)
overnight and blocked for 25 min with PBS-T BND
(PBS + 0.05% Tween-20 + 0.05% BND [5-bromo-5-nitro-
1,3-dioxane; SDT, Baesweiler, Germany]) + 0.2% bovine
serum albumin (BSA; Carl Roth, Karlsruhe, Germany). Fi-
nally, frits were prepared for drying by 1 h of incubation
with PBS-T BND+ 1% BSA + 5% saccharose and air-dried
at 35 °C for 30 min in a fluid bed dryer (FBD2000;
Endecotts, London, UK). The columns were equipped
with antibody-coated frits between two preblocked sep-
aration frits (Type 187; Porex) and stored dry at room
temperature until further use.
The principle of ABICAP™ immunofiltration assay
(Antibody Immuno Column for Analytical Processes,
Senova GmbH, Weimar, Germany) is shown in Fig. 1.
500 μL of pre-diluted sample material (UCBS casein
buffer, SDT) were applied per column and incubated
for 6 min. After a washing step with 750 μL of washing
buffer (PBS-T BND + 0.1% BSA), 500 μL of biotinylated
mAb A3/710–20 (in AA1-buffer [SDT]) were added
and incubated for 6 min. Columns were washed again
and incubated with 500 μL of streptavidin-PolyHRP 40
(SA-pHRP; in SA1-buffer, both SDT) for 6 min. Two
washing steps later (1 × 750 μL of washing buffer, 1 ×
750 μL of substrate buffer [phosphate/citrate buffer,
pH 5.0]) 500 μL of precipitating TMB substrate (epTMB;
SDT) were added for 6 min. Finally, columns were washed
with 750 μL of substrate buffer, and the extinctions were
read at 525 nm with a handheld photometer device
(Senova; Fig. 1).
To allow for maximum sensitivity of detection at low
background, both SA-pHRP and biotinylated detection
antibodies were titrated (0.1, 0.5, 1, and 5 μg/mL) in the
absence of antigen. For titration of SA-pHRP, the proto-
col was performed as described, but instead of biotinyl-
ated detection antibody AA1-buffer only was added. For
titration of biotinylated detection antibodies, SA-pHRP
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in the previous experiment. Low background was ob-
tained with mAb A3/710 at 0.5 μg/mL and SA-pHRP
at 0.5 μg/mL (Additional file 1: Figure S1).
The cutoff to determine the limits of detection (LOD)
and to discern positive from negative samples was calcu-
lated as the mean + 3 × standard deviation of negative
control columns (buffer only, n = 16). The assay’s sensi-
tivity was determined by measuring the LOD for recom-
binant A27. The assay’s specificity was determined for
various OPV strains by using purified viral particles and
by testing clinical crust material from CPXV-infected
patients. To determine the test’s specificity, additional
viruses causing similar clinical pictures were used, in-
cluding HSV-1 and PPV. The LOD was determined by
measuring serial dilutions of semi-purified virus particles
and virus from clarified cell culture supernatant. Finally,
the OPVABICAP assay was validated with a blinded panel
of PCR-quantified highly pathogenic viruses, including
Yellow Fever virus, Ebola virus, Marburg virus, VACV, and
MPXV.
Results
To establish the ABICAP assay, two high-affinity and
epitope-matched monoclonal antibodies targeting the
orthopoxviral attachment protein A27 were tested: mAb
A1/40 and mAb A3/710. Based on previous results from
sandwich-ELISAs, mAb A1/40 was immobilized as a
capture ELISA while biotinylated mAb A3/710 was used
as detection antibody. This combination proved superior
to all other combinations tested with 8 monoclonal anti-
bodies targeting A27 [11].
Detection limits
To determine the overall sensitivity of the ABICAP as
compared to the previously established sandwich-ELISA
based on the same two antibodies implemented in the
ABICAP assay, we determined the LOD for recombinantFig. 2 Titration of recombinant A27 proteins and different OPV strains to d
recombinant A27 (BEI Resources). b Results of titration of Vaccinia virus (VACV
Ectromelia virus (ECTV), and Variola virus (VARV) on ABICAP columnsA27 (Fig. 2a). Here, 56 pg/mL of recombinant A27 could
be detected which is approximately ten times higher as
compared to the LOD by ELISA of 5 pg/mL [11]. The
higher LOD was mainly caused by the highly stringent
cutoff of 0.417, which was calculated based on testing
negative controls of several batches of ABICAP columns
in independent experiments. If only the negative con-
trols of the titration experiment were used to calculate
the cutoff (0.234), a comparable sensitivity of 17 pg/mL
was achieved.
Using the presented protocol, all OPV strains tested
were detected with sensitivities of 3.4 × 104 PFU/mL for
VACV, 2.4 × 104 and 8.3 × 103 PFU/mL for VARV (Solaiman
and Niger strain, respectively), 6.8 × 103 PFU/mL for CPXV,
1.3 × 103 PFU/mL for MPXV, and 6.8 × 103 PFU/mL for
CMLV (Fig. 2b). ECTV showed a significantly increased
LOD (1.9 × 106 PFU/mL), which was expected since a
previous study showed impaired binding of capture
antibody A1/40 to ECTV [11]. As ECTV does not cause
zoonotic disease in humans and usually only infects la-
boratory mice, the lacking sensitivity is irrelevant for
clinical application of the OPV ABICAP assay.
Analysis of clinical samples
Our main goal was to establish a rapid POC diagnostics
system for OPV detection. We therefore tested whether
the established OPV ABICAP assay was able to detect
virus particles from clinical specimens. To this aim, we
used biopsy material (crust, skin biopsy, and swab of crust)
from two CPXV infections which had been diagnosed as
CPXV positive by qPCR. Homogenized crusts of either un-
known etiology (OPV negative by PCR) or those positive
for Myxoma virus as well as a surface swab sample positive
for Varizella zoster virus were included to test the specifi-
city of the ABICAP assay. Cell culture supernatants from
PPV and HSV-1 infections were used as negative control.
The clinical material that was tested positive for OPV by
PCR could be diagnosed as positive by the OPV ABICAPetermine detection limit for the ABICAP assay. a Results of titration for
), Cowpox virus (CPXV), Camelpox virus (CMLV), Monkeypox virus (MPXV),
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0.417, the cat skin biopsy with a corresponding qPCR CT
value of 27.5 showed significantly higher signals than
PPXV or HSV-1 used as negative control. No false-positive
results were obtained for homogenized crusts of either un-
known etiology or caused by Myxoma virus. The assay also
showed no cross-reactivity against a sample positive for
Varizella zoster virus. Most importantly, the swabbed crust
sample was unambiguously positive, indicating that non-
invasive sampling of crusts and rapid testing by the OPV
ABICAP assay is possible, which turns the assay into a
promising tool in field diagnostics.
Application of the ABICAP OPV assay in an external
quality assessment for diagnostics of BT samples
To evaluate further the ability of the OPV ABICAP assay
to detect OPV and differentiate them from other poten-
tial bioterror agents, a panel of PCR-quantified gamma
irradiation-inactivated viruses was tested (Table 2). The
panel was analyzed in a blinded fashion and was un-
blinded after reporting of the results. Here, VACV could
be detected down to a CT value of 30.7 corresponding to
6.4 × 104 genome equivalents (GE)/mL. The highest dilu-
tion at a CT value of 37.98 (2.3 × 10
3 GE/mL) could not
be detected, which is in agreement with the titration ex-
periments. In addition, to our knowledge OPV prepara-
tions contain at least 10-fold higher viral genome loads
than infectious particles, meaning that the particle con-
centration in this sample was significantly lower. MPXV
was also reliably detected, while no cross-reactivity could
be seen against Ebola virus, Marburg virus, and Yellow
fever virus.
In conclusion, the OPV ABICAP assay was able to de-
tect OPV rapidly from clinical specimens as well as from
blinded samples included in a bioterror panel. The assay
was sufficiently sensitive to confirm the virus presenceTable 1 Validation of the OPV ABICAP assay with clinical samples
Sample Source Diagnosed as qPCR
Cat, homogenized crust Cowpoxd 17.4 (1
Cat, homogenized skin biopsy Cowpoxd 27.5 (1
Human, homogenized crust Cowpoxd 11.7 (8
Human, swab of crust Cowpoxd 19.6 (3
Human, homogenized crust Unknown (OPV + PPV PCR negative) n.a.
Rat, homogenized crust Unknown (OPV PCR negative) n.a.
Rabbit, homogenized crust Myxomavirus n.a.
Human, swab of rash Varizella zoster 29.5
Cell culture Parapox virus -
Cell culture Herpes simplex virus -
aIn parentheses: estimation of genome equivalents in undiluted samples. For negat
titer of tested 1:10 dilutions
b,dFor scarce sample material, tested in two dilutions (1:10 and 1:50). Anywhere else
cA525nm < 0.417 (cutoff): - (negative), 0.417 < A525nm < 1.0: + (positive), 1.0 < A525nm :+in all clinical samples. The observed LOD for real-world
samples measured with the OPV ABICAP assay corre-
sponded to approximately 5 × 104 GE/mL.Discussion and conclusions
Molecular diagnostics of infectious diseases has under-
gone a rapid development over the past years. While there
are numerous commercially available tests for clinically
relevant infectious diseases, there is an obvious gap re-
garding tests for rare or emerging diseases, particularly
with respect to on-site diagnostic tests. Although un-
rivalled in sensitivity and specificity, PCR has its draw-
backs in field diagnostics, requiring a certain amount of
technical equipment, practical skills, and diagnostic know-
ledge. In contrast, so-called rapid tests like lateral flow as-
says (LFA) usually circumvent these demands and are easy
to perform, but lack sensitivity due to the absence of a sig-
nal amplification step. However, they present a promising
approach for POC diagnostics.
The established OPV ABICAP immunofiltration assay
is the first POC detection assay covering all zoonotic
OPV as well as VARV with a satisfactory sensitivity. One
previously developed handheld rapid test for poxviruses,
the Tetracore Orthopox Biothreat detection assay, dis-
plays an LOD of 106 to 107 PFU/mL which is usually
sufficient for the diagnosis of skin lesions containing ex-
tremely high viral loads [20]. The new OPV ABICAP
assay offers an LOD as low as 104 PFU/mL which allows
reliable diagnosis even when viral loads in the sample
are low because of inappropriate sampling or non-optimal
time points in the course of infection. Similarly, an
ABICAP assay for the detection of Ebola virus showed
an LOD of approximately 1.2 × 104 PFU/mL, indicating
that ABICAP systems generally represent sensitive plat-
forms for particle detection [10]. Additionally, the[CT]
a Tested Dilution ABICAPb [A525nm] Result
c
.6 × 109 GE/mL) 1:50/1:250 2.398/1.033 ++/++
.4 × 106 GE/mL) 1:50/1:250 0.390/0.249 ±/-
.2 × 1010 GE/mL) 1:50/1:250 1.428/0.446 ++/+
.4 × 108 GE/mL) 1:10/1:50 1.912/0.987 ++/+
1:50 0.334 ± 0.049 -
1:50 0.245 ± 0.007 -
1:50 0.305 ± 0.092 -
1:50 0.285 ± 0.007 -
1:10 (2.5 × 105TCID50/ ml) 0.275 ± 0.022 -
1:10 (6.9 × 107 PFU/ ml) 0.235 ± 0.065 -
ive controls (Parapox virus and herpes simplex virus cell culture supernatant):
, duplicate measurements (mean ± standard deviation of n = 2)
+ (highly positive). ±: borderline positive, see text
Table 2 Validation of the OPV ABICAP assay in an external quality assessment for diagnostics of BT samples
Virus qPCR [CT] Genome equivalents tested [GE/mL] ABICAP
a [A525nm] Result
Monkeypox 27.0 9.2 × 105 1.570 ± 0.001 ++
Vaccinia 22.5 2.4 × 107 2.032 ± 0.185 ++
Vaccinia 30.7 6.2 × 104 0.437 ± 0.023 +
Vaccinia 38.0 2.3 × 103 0.119 ± 0.016 -
Ebola 23.5 2.7 × 106 0.169 ± 0.009 -
Marburg 23.3 8.2 × 106 0.152 ± 0.050 -
Yellow fever n.d.b - 0.194 ± 0.004 -
Cell culture medium (DMEM) - - 0.181 ± 0.005 -
aMean ± standard deviation of n = 2
bNot determined
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comparable to the Tetracore assay time.
The higher sensitivity of the ABICAP assay compared
to lateral flow assays is also in agreement with previous
reports with an ABICAP assay targeting botulinum
neurotoxin. Furthermore, in an independent evaluation
the ABICAP showed sensitivity comparable to that of an
in-house ELISA whereas commercial LFAs either failed
completely or lacked sensitivity, even compared to the
relatively high LODs according to the manufacturers
[21]. Our study also shows that well-characterized anti-
bodies can easily be transferred from ELISA to ABICAP
assays. Here, the specific characteristics of the immu-
nofiltration approach offer the clear advantage of rela-
tive simplicity and rapid assay times at comparable
sensitivity.
Particularly when performing field diagnostics, ad-
equate sampling and sample processing can be impaired
dramatically by environmental conditions. Although the
ABICAP assay was highly specific for all samples tested
in this work, false-positive results remain a risk as in any
diagnostics, especially when testing clinical sample mater-
ial. Independent of the high specificity of the implemented
antibodies, matrix effects might cause higher background
signals. For an exhaustive validation, more samples, ideally
in the field, will be required to be analyzed using this
assay.
Finally, as all reagents for an OPV ABICAP test can be
stored stably at 4 °C or even ambient temperature, there
is no need to freeze reagents to -20 °C, which is usually
a limiting factor in the regions in which the diagnosed
diseases are endemic. The OPV ABICAP assay is there-
fore a low-tech alternative, particularly when compared
to PCR, and represents an optimal compromise between
ease of handling and sensitivity. Most importantly, not
only was the ABICAP system able to detect OPV from
clinical samples, but also to differentiate OPV from
other viruses that can (like OPV) cause skin lesions or
potentially be used as bioterror agents.Additional file
Additional file 1: Figure S1. Titration of SA-pHRP and biotinylated
detection antibody A3/710. Working concentrations for both SA-pHRP
(A) and A3/710 (B) were determined by testing four concentrations
(0.1, 0.5, 1, 5 μg/mL), using the ABICAP protocol to minimize background
binding caused by too high antibody or enzyme concentrations (TIF 164 kb)
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